Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Hongwei & Li
DAF-FM fluorescence can be detected by any instrument that can detect fluorescein
The effect of Seviteronel (VT-464) and AA on MDA-PCa-133 growing in tumor-bearing castrated male mice: randomization into three groups
Cyclopamine has been used in stem cell differentiation
p110δ inactivation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression
Laquinimod Catalog No.:M11360-2 Hongwei & LiLaquinimod, also known as, is an experimental immunomodulator developed by Active Biotech and Teva. It is being investigated as an oral treatment for multiple sclerosis (MS). Laquinimod is the successor of Active Biotech's failed experimental immunomodulator linomide. Laquinimod seems to be able to reduce the MS disease activity on MRI. In 2011, Teva announced its clinical trials involving laquinimod had failed, being unable to significantly reduce
US$ 15.20
US$ 1750.00